Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasis.

Shen, Qian; Liu, Rong; Tan, Shiyu; Xu, Xiaoding; Fang, Junyue; Li, Rong

Shen, Qian; Liu, Rong; Tan, Shiyu; Xu, Xiaoding; Fang, Junyue; Li, Rong.

Afiliação

Shen Q; Department of Pharmacy & Pharmacology and the Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Liu R; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Tan S; Department of Pharmacy & Pharmacology and the Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Xu X; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Fang J; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Li R; Department of Pharmacy & Pharmacology and the Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.

Front Immunol ; 13: 1089262, 2022.

Article em En | MEDLINE | ID: mdl-36618400

Assuntos

MicroRNAs; Nanopartículas; Psoríase; Humanos; Pele; Psoríase/tratamento farmacológico; Psoríase/etiologia; MicroRNAs/farmacologia; Predisposição Genética para Doença

Palavras-chave

autoimmune disease; nanoparticles; pathogenesis; psoriasis; psoriasis treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / MicroRNAs / Nanopartículas Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google